Translational research

24P - A new bioinformatic pipeline allows the design of small, targeted gene panels for efficient TMB estimation

Authors
  • P. Manca (Rome, Italy)
  • I. Mallona (Zürich, Switzerland)
  • D. Santini (Roma, Italy)
  • G. Tonini (Roma, Italy)
  • C. Rolfo (Baltimore, United States of America)
  • M. Robinson (Zürich, Switzerland)
  • F. Pantano (Roma, Italy)
Speakers
  • P. Manca (Rome, Italy)

Previous ePoster
22P - Paclitaxel/ carboplatin/ bevacizumab in non-small cell lung cancer patients induces peripheral effector CD8 T cell proliferation that could be prone for treatment with checkpoint inhibitors

Next ePosters
29P - Pretreatment T790M mutation detection by ultrasensitive PCR assay as predictor of efficacy in non-small lung cancer (NSCLC) patients treated with 1st or 2nd generation EGFR tyrosine kinase inhibitors (TKIs)
30P - Prognostic significance of IGF-1 signaling pathway in patients with advanced non-small cell lung cancer
31P - Do two lungs form an integrated immune system? Learning from BALF examination in lung cancer
33P - Prognostic value of CD8-positive tumor stroma-infiltrating lymphocytes and PD-L1 positive tumor cells at initial biopsy in patients with locally advanced NSCLC treated with chemoradiotherapy
35P - Clinicopathological characteristics with genetic profiling and prognostic analysis of primary lymphoepithelioma-like carcinoma in Chinese south-eastern population
36P - Can a BALF profile distinguish hot vs cold lung tumors?
38P - Hedgehog pathway activation might mediate pemetrexed resistance in NSCLC cells
41P - Diagnostic accuracy of droplet digital PCR (ddPCR) and amplification refractory mutation system PCR (ARMS-PCR) for detecting EGFR mutation in cell-free DNA of advanced lung cancer: A meta-analysis
44P - Temporal trends in treatment (Tx) and overall survival (OS) among patients (pts) with incident NSCLC in the UK: A real-oncology database analysis from the I-O Optimise initiative
45P - Treatment (Tx) patterns and overall survival (OS) in patients (pts) with stage IIIB–IV NSCLC in Portugal: An IPO-PORTO database analysis from the I-O Optimise initiative